Find and Pitch Jounalists, Get Your Story Covered

Tags: Celltrion subcutaneous infliximab inflammatory bowel disease infliximab infection

	Profile	Recent Articles on Subject
1	Tara Haelle MedPage Today Sci/health journalist. Feminist. Educator. Photographer. Author. DFW science journalismhealthphotographyteaching	Studies Point to Several Options for Ulcerative Colitis After Anti-TNF Failure - 11 days ago Mirikizumab Effective in Crohn's Disease After Initial Standard Therapy Failure - 3 months ago Risankizumab Beats Ustekinumab for Previously Treated Crohn's - 12 months ago
2	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Dual Immunotherapy Shows Promise in MSI-H/dMMR Metastatic Colorectal Cancer - 18 days ago FDA Approves Axatilimab-csfr 9 mg and 22 mg Vial Sizes for cGVHD - about 1 month ago Ustekinumab-stba Receives FDA Approval for Autoimmune Disorder and Inflammatory Bowel Disease - 2 months ago New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer - 7 months ago J&J Submits sBLA To FDA for Guselkumab in Ulcerative Colitis - 12 months ago Treatment With Anifrolumab-fnia Shows Promising Rates of Remission for Lupus - over 1 year ago
3	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Amgen’s lung cancer treatment gets conditional approval - about 2 months ago Imfinzi receives NICE recommendation for lung cancer treatment - 3 months ago Celltrion unveils promising dose escalation results for subcutaneous infliximab - 4 months ago Amgen’s trial brings new hope for IgG4-RD patients - 9 months ago
4	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Tislelizumab in Combination With Chemotherapy for Gastric, Gastrosophageal Junction Adenocarcinoma - about 2 months ago FDA Approves Ustekinumab-kfce as Biosimilar to Ustekinumab - 3 months ago FDA Grants Breakthrough Therapy Designation for Nipocalimab to Treat Sjögren Disease - 3 months ago FDA Accepts Biologic License Application for Biosimilar Denosumab - 4 months ago Non-Medical Switch to Infliximab Biosimilar Demonstrates Similar Outcomes for IBD - 5 months ago FDA Approves Guselkumab for Treatment of Ulcerative Colitis - 5 months ago FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 8 months ago FDA Accepts sBLA for Bimekizumab-bkzx in Hidradenitis Suppurativa Treatment - 11 months ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - 12 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 12 months ago FDA Approves Adalimumab-ryvk as Interchangeable Biosimilar for Humira - 12 months ago Biosimilar Adalimumab, Etanercept Have Equivalent Effectiveness to Reference Drugs Over 48 Months - about 1 year ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - about 1 year ago FDA Approves Targeted Release Budesonide for Treatment of Primary Immunoglobulin A Nephropathy - about 1 year ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - about 1 year ago FDA Accepts Supplemental Biologics License Application for Hadlima for Interchangeability With Humira - over 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - over 1 year ago Subcutaneous Lecanemab Demonstrates Greater Amyloid Plaque Removal Than Intravenous Lecanemab - over 1 year ago
5	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma - about 2 months ago Inebilizumab for Myasthenia Gravis Reduces Steroid Burden - 4 months ago Dupilumab Reduces Airway Inflammation, Mucus Plugs in Asthma Patients - 11 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - about 1 year ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - about 1 year ago New Data on Bimekizumab in Psoriatic Arthritis - about 1 year ago A Novel Mechanism of Action in Treating Relapsing MS - over 1 year ago New Data on CD40 Ligand Inhibitor for Relapsing MS - over 1 year ago
6	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug - 2 months ago
7	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	STAT+: For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission - 2 months ago
8	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma - 3 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 5 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 6 months ago Axatilimab Shows Efficacy in Recurrent/Refractory GVHD - about 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - over 1 year ago
9	John Gever MedPage Today MedPage Today factotum. Pittsburgh, Pa. Healthcare journalism	Novel Anti-IgG Drug Hits Mark in Sjogren's Patients - 3 months ago Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus - 6 months ago Medicare Lags, Medicaid Leads for Biosimilar Uptake - 7 months ago Study Confirms: No Great Options for Treating VEXAS - 9 months ago Novel IL-17A Blocker Continues to Impress in PsA - over 1 year ago Novel Drug OK'd for Ulcerative Colitis - over 1 year ago Bimekizumab Data in axSpA Look Good Through 1 Year - over 1 year ago
10	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 4 months ago Alternative Pathway Inhibition Makes Good in IgA Nephropathy - 4 months ago

Journalists covering infliximab